Guru Ownership Trend
Guru Analysis for Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Inc. (XENE), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q2 2026, a total of 6 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $42.69 M.
Top institutional holders include Paul Tudor Jones and Stanley Druckenmiller.
Institutional sentiment is currently Bullish. This is evidenced by a $7.96 M net inflow during the quarter.
Recent activity highlights Steven Cohen who opened a new position. Conversely, Renaissance Technologies (RenTech) reduced exposure by 37.7%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q2 2026)
Guru Consensus (Q2 2026)
FAQs for Xenon Pharmaceuticals Inc. (XENE)
Major holders include Paul Tudor Jones ($32.92 M), Stanley Druckenmiller ($14.4 M), Renaissance Technologies (RenTech) ($11.29 M). According to the latest reported data, 6 tracked investment managers collectively hold approximately 1.17 M shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $7.96 M, with 3 managers increasing positions and 2 managers reducing holdings.
During the most recent reporting period, 2 managers trimmed their positions, while 0 fully exited XENE. The total reported sell value was $6.85 M.
Yes, 2 managers opened new positions in XENE, and 1 increased their existing holdings. The total reported buy value was $14.8 M.
